Table 1.

Clinical information of the studied CD patients.

		CD patients [n = 73]
		Fibrostenosing CD patients [n = 44]	Non fibrostenosing CD patients [n = 29]
Age [median, range] years		31 [17–72]	43 [21–68]
Male gender [n, %]		22; 50.0	12; 41.4
Disease duration [median, range] years		8.7 [0.2 - 51.5]	10.19 [0.07–40.42]
CD treatment [*stopped before surgery]	Infliximab* [n]	5	3
	Adalimumab* [n]	15	6
	Vedolizumab [n]	1	0
	Azathioprine [n]	10	5
	Mercaptopurine [n]	3	5
	Methotrexate [n]	2	2
	Corticoids [n]	7	3
	5ASA [n]	0	5
	None [n]	11	9
Smoking	Active smokers [n]	16	11
	Former smokers [n]	8	6
	Non-smoker [n]	19	11
	Unknown [n]	1	1

The five patients included in the proteomic study came from the 44 fibrostenosing CD patients of the IHC study (60% males; median [range] age: 33 years [22–41]; median [range] disease duration: 8.2 years [4.4–12.3]; 60% active smokers; one patient was treated by infliximab, three patients were treated by adalimumab [in monotherapy for one patient and in a combination therapy with azathioprine for one and with corticoids for the another], and the last patient was treated by corticoids alone.

*In a combination therapy with immunomodulator or corticoids for some patients.

CD, Crohn’s disease; 5-ASA, 5-aminosalicylate; IHC, immunohistochemical.